Citius Oncology (CTOR) Competitors $1.97 +0.02 (+1.03%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.98 +0.01 (+0.51%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. BCAX, ORKA, KURA, ATAI, VALN, SEPN, RAPP, OPT, ATYR, and SIGAShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Bicara Therapeutics (BCAX), Oruka Therapeutics (ORKA), Kura Oncology (KURA), atai Life Sciences (ATAI), Valneva (VALN), Septerna (SEPN), Rapport Therapeutics (RAPP), Opthea (OPT), aTyr Pharma (ATYR), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Bicara Therapeutics Oruka Therapeutics Kura Oncology atai Life Sciences Valneva Septerna Rapport Therapeutics Opthea aTyr Pharma Siga Technologies Bicara Therapeutics (NASDAQ:BCAX) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations. Do institutionals and insiders hold more shares of BCAX or CTOR? 70.5% of Citius Oncology shares are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend BCAX or CTOR? Bicara Therapeutics presently has a consensus price target of $31.86, suggesting a potential upside of 171.14%. Citius Oncology has a consensus price target of $3.00, suggesting a potential upside of 52.28%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings & valuation, BCAX or CTOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$68MN/AN/ACitius OncologyN/AN/AN/AN/AN/A Does the media refer more to BCAX or CTOR? In the previous week, Citius Oncology had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 2 mentions for Citius Oncology and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.82 beat Citius Oncology's score of 1.24 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Bicara Therapeutics Very Positive Citius Oncology Positive Is BCAX or CTOR more profitable? Bicara Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Citius Oncology N/A -53.88%-18.86% SummaryBicara Therapeutics beats Citius Oncology on 8 of the 10 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$154.39M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E RatioN/A21.1828.1020.05Price / SalesN/A288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book3.088.378.665.87Net IncomeN/A-$55.19M$3.25B$258.55M7 Day Performance28.76%5.88%4.23%3.74%1 Month Performance-43.71%17.33%10.52%11.75%1 Year PerformanceN/A4.42%34.41%18.03% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology1.7523 of 5 stars$1.97+1.0%$3.00+52.3%N/A$154.39MN/A0.00N/APositive NewsAnalyst UpgradeGap UpBCAXBicara Therapeutics2.0922 of 5 stars$10.18+4.8%$31.86+213.0%N/A$555.22MN/A0.0032ORKAOruka Therapeutics2.7217 of 5 stars$14.70+3.3%$40.38+174.7%N/A$550.37MN/A-3.26N/AUpcoming EarningsAnalyst ForecastKURAKura Oncology4.4987 of 5 stars$6.35+1.1%$24.50+285.8%-70.0%$549.72M$53.88M-3.02130Positive NewsATAIatai Life Sciences3.321 of 5 stars$2.72+3.8%$9.00+230.9%+125.9%$544.92M$1.86M-2.9980News CoverageVALNValneva1.9691 of 5 stars$6.32+4.1%$15.50+145.3%+5.8%$537.79M$186.06M-5.31700News CoverageGap UpSEPNSepterna1.4515 of 5 stars$12.01+2.4%$26.75+122.7%N/A$535.17M$1.08M0.00N/ANews CoverageRAPPRapport Therapeutics1.6466 of 5 stars$14.63+0.2%$28.00+91.4%-27.7%$534.00MN/A-4.24N/ANews CoverageOPTOpthea0.3324 of 5 stars$3.41+7.2%$1.33-60.9%+55.0%$524.83M$120K0.008News CoverageGap UpATYRaTyr Pharma2.1633 of 5 stars$5.53+4.3%$20.20+265.3%+161.4%$492.17M$230K-6.8353News CoverageGap UpHigh Trading VolumeSIGASiga Technologies1.9899 of 5 stars$6.86+1.3%N/A-28.7%$490.08M$138.72M10.2440News CoverageUpcoming EarningsOptions Volume Related Companies and Tools Related Companies Bicara Therapeutics Competitors Oruka Therapeutics Competitors Kura Oncology Competitors atai Life Sciences Competitors Valneva Competitors Septerna Competitors Rapport Therapeutics Competitors Opthea Competitors aTyr Pharma Competitors Siga Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTOR Stock Alerts